Circadian clock and breast cancer: A molecular link

Cell Cycle

Volumn 6, Issue 11, 2007, Pages 1329-1331

  Sahar, Saurabh ^a   Sassone Corsi, Paolo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Circadian rhythms; CLOCK; Cyclin D1; Estrogen receptor

Indexed keywords

CRYPTOCHROME 1; CYCLIN D1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HISTONE ACETYLTRANSFERASE; NUCLEIC ACID BINDING PROTEIN; PER1 PROTEIN; PER2 PROTEIN; PROTEIN BMAL1; PROTEIN BMAL2; PROTEIN P300; PROTEIN PER3; PROTEIN PS2; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; HISTONE; MELATONIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL STRESS; CIRCADIAN RHYTHM; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; MAMMARY GLAND; NONHUMAN; REVIEW; ACETYLATION; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CELL TRANSFORMATION; CHROMATIN; DEVELOPED COUNTRY; DISEASE PREDISPOSITION; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MAMMAL; METABOLISM; MOUSE; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; RISK; TUMOR SUPPRESSOR GENE;

ACETYLATION; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; CIRCADIAN RHYTHM; CYCLIN D1; DEVELOPED COUNTRIES; DISEASE SUSCEPTIBILITY; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; MAMMALS; MAMMARY NEOPLASMS, EXPERIMENTAL; MELATONIN; MICE; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RISK; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 34547662497     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.11.4295     Document Type: Review

References (30)

1. Stevens RG. Circadian disruption and breast cancer: From melatonin to clock genes. Epidemiology 2005; 16:254-8.
2. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001; 93:1563-8.
3. Stevens RG. Artificial lighting in the industrialized world: Circadian disruption and breast cancer. Cancer Causes Control 2006; 17:501-7.
4. Aubert C, Janiaud P, Lecalvez J. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J Neural Transm 1980; 47:121-30.
5. Mhatre MC, Shah PN, Juneja HS. Effect of varying photoperiods on mammary morphology, DNA synthesis, and hormone profile in female rats. J Natl Cancer Inst 1984; 72:1411-6.
6. Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell 2002; 111:919-22.
7. Hirayama J, Sassone-Corsi P. Structural and functional features of transcription factors controlling the circadian clock. Curr Opin Genet Dev 2005; 15:548-56.
8. Kondratov RV, Kondratova AA, Lee C, Gorbacheva VY, Chernov MV, Antoch MP. Post-translational regulation of circadian transcriptional CLOCK(NPAS2)/BMAL1 complex by CRYPTOCHROMES. Cell Cycle 2006; 5:890-5.
9. Antoch MP, Kondratov RV, Takahashi JS. Circadian clock genes as modulators of sensitivity to genotoxic stress. Cell Cycle 2005; 4:901-7.
10. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS, Hogenesch JB. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002; 109:307-20.
11. Hunt T, Sassone-Corsi P. Riding tandem: Circadian clocks and the cell cycle. Cell 2007; 129:461-4.
12. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003; 302:255-9.
13. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002; 111:41-50.
14. Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006; 125:497-508.
15. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005; 26:1241-6.
16. Metz RP, Qu X, Laffin B, Earnest D, Porter WW. Circadian clock and cell cycle gene expression in mouse mammary epithelial cells and in the developing mouse mammary gland. Dev Dyn 2006; 235:263-71.
17. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 2006; 22:375-82.
18. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 2005; 106:2827-36.
19. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92.
20. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003; 115:751-63.
21. Stossi F, Likhite VS, Katzenellenbogen JA, Katzenellenbogen BS. Estrogen-occupied estrogen receptor represses cyclin G2 gene expression and recruits a repressor complex at the cyclin G2 promoter. J Biol Chem 2006; 281:16272-16278.
22. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: Tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 2006; 66:6370-8.
23. Leader JE, Wang C, Popov VM, Fu M, Pestell RG. Epigenetics and the estrogen receptor. Ann NY Acad Sci 2006; 1089:73-87.
24. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000; 60:4026-9.
25. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 2003; 17:1681-92.
26. Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast 2006; 15:718-27.
27. Wang C, Fan S, Li Z, Fu M, Rao M, Ma Y, Lisanti MP, Albanese C, Katzenellenbogen BS, Kushner PJ, Weber B, Rosen EM, Pestell RG. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res 2005; 65:6557-67.
28. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005; 14:R85-92.
29. Zhang K, Dent SY. Histone modifying enzymes and cancer: Going beyond histones. J Cell Biochem 2005; 96:1137-48.
30. Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol 2005; 25:3109-16.